Related Experiment Video
Updated: Jul 9, 2026
08:53
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
9.2K
Monitoring denosumab therapy using the calcium isotope marker (CIM) technology
Anton Eisenhauer1, Sönke Sönnichsen2, Agustina Hastuti3
1GEOMAR Helmholtz Centre for Ocean Research Kiel, Kiel, Germany; Osteolabs GmbH, Kiel, Germany.
Bone
|May 15, 2025
Summary
Calcium Isotope Markers (CIM) show potential for personalized osteoporosis treatment monitoring. This pilot study suggests CIM may offer a more sensitive approach than traditional methods like DXA for tracking denosumab therapy response in postmenopausal women.
Area of Science:
- Endocrinology
- Metabolic Bone Disease
- Biomarker Discovery
Background:
- Osteoporosis management relies on Dual-energy X-ray absorptiometry (DXA) and bone turnover markers (BTMs) for monitoring treatment efficacy.
- These established methods may lack the sensitivity for detecting individualized responses to therapies like denosumab.
- Calcium (Ca) Isotope Markers (CIM), measuring stable Ca isotope ratios in serum and urine, present a novel approach for assessing bone health.
Purpose of the Study:
- To evaluate the potential of Calcium Isotope Markers (CIM) as a sensitive tool for monitoring denosumab therapy in postmenopausal women with osteoporosis.
- To compare the responsiveness of CIM with traditional markers like DXA and BTMs in tracking bone mineral density and turnover.
- To explore the correlation between CIM, parathyroid hormone (PTH), and Ca balance during osteoporosis treatment.
Main Methods:
- A pilot study involving 13 postmenopausal women with osteoporosis initiated on denosumab therapy.
- Serial measurements of CIM_serum, CIM_urine, BMD, BTMs, and PTH were collected over 24 weeks.
- Analysis included applying CIM thresholds to distinguish net bone calcium uptake from efflux and correlating CIM with PTH and DXA/BTM data.
Main Results:
- Baseline CIM indicated net bone calcium loss, which shifted towards uptake after denosumab initiation, with significant changes observed within one week.
- CIM_serum and CIM_urine values showed a positive correlation with PTH levels.
- Individual patient responses varied, with some exceeding CIM thresholds rapidly while others showed slower or transient changes; DXA confirmed group-level gains, but BTMs did not reflect individual CIM variations.
Conclusions:
- Calcium Isotope Markers (CIM) demonstrate potential as a sensitive, individualized biomarker for monitoring denosumab therapy response in osteoporosis.
- CIM may offer advantages over traditional methods like DXA and BTMs in detecting nuanced, patient-specific changes in bone calcium dynamics.
- Further validation in larger, controlled studies is necessary to establish CIM's role in personalized osteoporosis management.
Related Concept Videos
01:20¹³C NMR: Distortionless Enhancement by Polarization Transfer (DEPT)
When proton-coupled carbon-13 spectra are simplified by a broadband proton decoupling technique, structural information about the coupled protons is lost. Distortionless enhancement by polarization transfer (DEPT) is a technique that provides information on the number of hydrogens attached to each carbon in a molecule. While the DEPT experiment utilizes complex pulse sequences, the pulse delay and flip angle are specifically manipulated. The resulting signals have different phases depending on...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:26Differential Staining Technique
Differential staining is an essential microbiological technique that exploits variations in cell wall structures to classify and identify microorganisms. It facilitates the distinction of bacteria, aiding in diagnostic and research applications. Two of the most widely used differential staining methods are Gram staining and acid-fast staining, both of which rely on the chemical and structural differences in bacterial cell walls.Gram Staining TechniqueGram staining differentiates bacteria by...